Mode
Text Size
Log in / Sign up

Robot-assisted inguinal lymphadenectomy reduces the odds of total postoperative complications in penile cancer patientsRobot surgery may reduce complications for penile cancer patients

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that RAIL reduces odds of total complications, but evidence remains low certainty due to study limitations.

This meta-analysis evaluated the efficacy of robot-assisted inguinal lymphadenectomy (RAIL) compared to open inguinal lymph node dissection (OILND) in patients with penile cancer. The analysis included 276 patients across multiple studies to compare surgical outcomes, including operative time, blood loss, and various complication types.

The primary finding indicated that RAIL was associated with a lower risk of total postoperative complications (OR 0.52; 95% CI: 0.27, 0.97; P = 0.047). However, other outcomes such as lymph node yield and skin-related complications showed no significant differences between the two surgical approaches. Operative times tended to be longer with RAIL, while findings for estimated blood loss and drainage-related outcomes were inconsistent across studies.

The authors noted several limitations, including a small number of retrospective studies and extreme between-study heterogeneity for continuous perioperative variables. Consequently, the GRADE assessment indicated low certainty of evidence for most pooled outcomes and very low certainty for skin-related complications and lower-limb edema. While RAIL may be associated with fewer overall postoperative complications than open surgery, the current evidence is insufficient to establish a definitive morbidity-reduction benefit.

When patients with penile cancer undergo surgery to remove lymph nodes in the groin, they face risks like infection or swelling. A review of data from 276 patients looked at whether using a robot during this procedure changed those outcomes compared to traditional open surgery.

The analysis found that patients who had the robot-assisted procedure were less likely to experience total postoperative complications. However, while the robot helped reduce these issues, it generally took more time for surgeons to complete the operation. Other factors, such as how many lymph nodes were found or the amount of blood lost during surgery, did not show a clear difference between the two methods.

It is important to note that because this review relied on a small number of older studies, the level of certainty for these results is low. While the robot shows promise in reducing complications, there isn't enough consistent data yet to say it is definitely better than traditional surgery in every case.

What this means for you:
Robot-assisted surgery may lower overall complication rates for penile cancer patients, but more high-quality data is needed.

Common questions

Is robot-assisted surgery safer for penile cancer patients?

The study found that patients who had the robot-assisted procedure had lower odds of total postoperative complications. However, because the evidence is based on a small number of studies and has low certainty, it is not yet possible to say if it is definitively safer than traditional open surgery.

How does robot-assisted surgery compare to open surgery in terms of time?

The findings showed that the operative time generally tended to be longer when using the robot-assisted method compared to the standard open procedure. Other factors, like skin complications or the number of lymph nodes found, did not show a significant difference between the two methods.

What are the limitations of this finding?

The evidence is considered low certainty because it relied on a small number of retrospective studies. There was also a lot of variation between different studies, which makes it hard to confirm exactly how much benefit the robot provides for patients.

Study Details

Study typeMeta analysis
Sample sizen = 276
EvidenceLevel 1
PublishedJun 2026
View Original Abstract ↓
This focused systematic review and meta-analysis evaluated robot-assisted inguinal lymphadenectomy (RAIL) versus open inguinal lymph node dissection (OILND) in penile cancer, aiming to provide robot-specific comparative estimates rather than a broad minimally invasive synthesis. PubMed, EMBASE, Web of Science, and the Cochrane Library were searched through December 2025 for comparative studies. All meta-analyses were conducted using STATA 18, employing random-effects modeling. Binary outcomes were summarized using odds ratios (ORs), and continuous outcomes were presented as weighted mean differences (WMDs), with all estimates accompanied by 95% confidence intervals (CIs). Risk of bias in the included non-randomized comparative studies was assessed using the ROBINS-I tool. Four retrospective comparative studies involving 276 patients were included, and no randomized controlled trials were identified. A lower odds of total postoperative complications was observed with RAIL (OR = 0.52, 95% CI: 0.27, 0.97; P = 0.047), but this borderline finding should be interpreted cautiously given the small number of retrospective studies and potential residual confounding. Across individual studies, operative time generally tended to be longer with RAIL, whereas findings for estimated blood loss and drainage-related outcomes were inconsistent. Lymph node yield, skin-related complications, minor complications, and groins with positive nodes did not differ significantly between approaches. According to the GRADE assessment, the certainty of evidence was low for most pooled outcomes and very low for skin-related complications and lower-limb edema/lymphedema. RAIL may be associated with lower overall postoperative complications than open surgery, but the evidence remains low certainty and insufficient to establish a definitive morbidity-reduction benefit. In addition, several continuous perioperative variables showed extreme between-study heterogeneity and were not clinically interpretable as reliable pooled effects.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.